+关注
cattyy
暂无个人介绍
IP属地：北京
59
关注
3
粉丝
0
主题
0
勋章
主贴
热门
cattyy
2020-06-02
$Zoom(ZM)$
开始放量了
cattyy
2020-06-02
$Zoom(ZM)$
啥赚钱赔钱的，刺激就完了！
cattyy
2020-04-28
$Zoom(ZM)$
这票真坚挺
cattyy
2020-04-25
$Zoom(ZM)$
zoom这种纯工具类app就是脆弱啊，被小扎一脚踹翻了…巨头之前没进入是因为没看上
cattyy
2020-04-25
$Zoom(ZM)$
什么情况？
cattyy
2020-04-14
现价138.9，这是来黑康希诺的？
大摩料康希诺生物(06185.HK)预防新冠疫苗最快年底有机会获批 目标价102元
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3461415218066278","uuid":"3461415218066278","gmtCreate":1498321197536,"gmtModify":1498321197536,"name":"cattyy","pinyin":"cattyy","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":59,"tweetSize":6,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":4,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.29","exceedPercentage":"93.08%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.80%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":7,"crmLevelSwitch":0,"location":"北京","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":2,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":958078377,"gmtCreate":1591108215999,"gmtModify":1704194418800,"author":{"id":"3461415218066278","authorId":"3461415218066278","name":"cattyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3461415218066278","idStr":"3461415218066278"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>开始放量了","listText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>开始放量了","text":"$Zoom(ZM)$开始放量了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/958078377","isVote":1,"tweetType":1,"viewCount":1066,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":958068837,"gmtCreate":1591104708929,"gmtModify":1704194361520,"author":{"id":"3461415218066278","authorId":"3461415218066278","name":"cattyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3461415218066278","idStr":"3461415218066278"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>啥赚钱赔钱的，刺激就完了！","listText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>啥赚钱赔钱的，刺激就完了！","text":"$Zoom(ZM)$啥赚钱赔钱的，刺激就完了！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/958068837","isVote":1,"tweetType":1,"viewCount":1680,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":925208951,"gmtCreate":1588007175973,"gmtModify":1704366100796,"author":{"id":"3461415218066278","authorId":"3461415218066278","name":"cattyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3461415218066278","idStr":"3461415218066278"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>这票真坚挺","listText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>这票真坚挺","text":"$Zoom(ZM)$这票真坚挺","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/925208951","isVote":1,"tweetType":1,"viewCount":940,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":925395360,"gmtCreate":1587753943950,"gmtModify":1704365566523,"author":{"id":"3461415218066278","authorId":"3461415218066278","name":"cattyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3461415218066278","idStr":"3461415218066278"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>zoom这种纯工具类app就是脆弱啊，被小扎一脚踹翻了…巨头之前没进入是因为没看上","listText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>zoom这种纯工具类app就是脆弱啊，被小扎一脚踹翻了…巨头之前没进入是因为没看上","text":"$Zoom(ZM)$zoom这种纯工具类app就是脆弱啊，被小扎一脚踹翻了…巨头之前没进入是因为没看上","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/925395360","isVote":1,"tweetType":1,"viewCount":1010,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":925399053,"gmtCreate":1587752286272,"gmtModify":1704365559391,"author":{"id":"3461415218066278","authorId":"3461415218066278","name":"cattyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3461415218066278","idStr":"3461415218066278"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>什么情况？","listText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>什么情况？","text":"$Zoom(ZM)$什么情况？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/925399053","isVote":1,"tweetType":1,"viewCount":1647,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":928543335,"gmtCreate":1586853258127,"gmtModify":1704362216743,"author":{"id":"3461415218066278","authorId":"3461415218066278","name":"cattyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3461415218066278","idStr":"3461415218066278"},"themes":[],"htmlText":"现价138.9，这是来黑康希诺的？","listText":"现价138.9，这是来黑康希诺的？","text":"现价138.9，这是来黑康希诺的？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/928543335","repostId":"2027225484","repostType":2,"repost":{"id":"2027225484","pubTimestamp":1586845740,"share":"https://www.laohu8.com/m/news/2027225484?lang=&edition=full","pubTime":"2020-04-14 14:29","market":"us","language":"zh","title":"大摩料康希诺生物(06185.HK)预防新冠疫苗最快年底有机会获批 目标价102元","url":"https://stock-news.laohu8.com/highlight/detail?id=2027225484","media":"AAFN","summary":"摩根士丹利发表报告表示，康希诺生物 旗下预防新冠肺炎疫苗之Ad5-nCoV即将进入第二试验阶段，为全球首个进入第二试验阶段的疫苗，将会有500人以中、低剂量或安慰剂接种疫苗，并在第0、14、28和1","content":"<html><body><p><a href=\"https://laohu8.com/S/MS\">摩根士丹利</a>发表报告表示，康希诺生物 旗下预防新冠肺炎疫苗之Ad5-nCoV即将进入第二试验阶段，为全球首个进入第二试验阶段的疫苗，将会有500人以中、低剂量或安慰剂接种疫苗，并在第0、14、28和180天测试血清样品。该行估计，该疫苗最快於今年底或可获批，管理层更不排除除了中国，同时在海外国家进行後期试验。报告又指，希诺生物亦正考虑生产的各种选择，包括斥资3亿至5亿元人民币建立新生产线或寻找商业制造合作夥伴等，然而合同制造组织是不被允许在中国生产疫苗。如果成功获得批准，希诺生物计划至少向所有前线和高危人士提供疫苗。但是，最终剂量尚未确定，因此在此阶段很难评估产量。该行维持其「跑赢大市」评级，目标价为102元。(sw/da)~阿思达克财经新闻网址: www.aastocks.com</p></body></html>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>大摩料康希诺生物(06185.HK)预防新冠疫苗最快年底有机会获批 目标价102元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n大摩料康希诺生物(06185.HK)预防新冠疫苗最快年底有机会获批 目标价102元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-04-14 14:29 北京时间 <a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1008314&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>摩根士丹利发表报告表示，康希诺生物 旗下预防新冠肺炎疫苗之Ad5-nCoV即将进入第二试验阶段，为全球首个进入第二试验阶段的疫苗，将会有500人以中、低剂量或安慰剂接种疫苗，并在第0、14、28和180天测试血清样品。该行估计，该疫苗最快於今年底或可获批，管理层更不排除除了中国，同时在海外国家进行後期试验。报告又指，希诺生物亦正考虑生产的各种选择，包括斥资3亿至5亿元人民币建立新生产线或寻找商业...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1008314&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/24fa8350588843d92f819ac12ab5ce16","relate_stocks":{"MS":"摩根士丹利","06185":"康希诺生物"},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1008314&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2027225484","content_text":"摩根士丹利发表报告表示，康希诺生物 旗下预防新冠肺炎疫苗之Ad5-nCoV即将进入第二试验阶段，为全球首个进入第二试验阶段的疫苗，将会有500人以中、低剂量或安慰剂接种疫苗，并在第0、14、28和180天测试血清样品。该行估计，该疫苗最快於今年底或可获批，管理层更不排除除了中国，同时在海外国家进行後期试验。报告又指，希诺生物亦正考虑生产的各种选择，包括斥资3亿至5亿元人民币建立新生产线或寻找商业制造合作夥伴等，然而合同制造组织是不被允许在中国生产疫苗。如果成功获得批准，希诺生物计划至少向所有前线和高危人士提供疫苗。但是，最终剂量尚未确定，因此在此阶段很难评估产量。该行维持其「跑赢大市」评级，目标价为102元。(sw/da)~阿思达克财经新闻网址: www.aastocks.com","news_type":1},"isVote":1,"tweetType":1,"viewCount":1186,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":958068837,"gmtCreate":1591104708929,"gmtModify":1704194361520,"author":{"id":"3461415218066278","authorId":"3461415218066278","name":"cattyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461415218066278","authorIdStr":"3461415218066278"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>啥赚钱赔钱的，刺激就完了！","listText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>啥赚钱赔钱的，刺激就完了！","text":"$Zoom(ZM)$啥赚钱赔钱的，刺激就完了！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/958068837","isVote":1,"tweetType":1,"viewCount":1680,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":925395360,"gmtCreate":1587753943950,"gmtModify":1704365566523,"author":{"id":"3461415218066278","authorId":"3461415218066278","name":"cattyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461415218066278","authorIdStr":"3461415218066278"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>zoom这种纯工具类app就是脆弱啊，被小扎一脚踹翻了…巨头之前没进入是因为没看上","listText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>zoom这种纯工具类app就是脆弱啊，被小扎一脚踹翻了…巨头之前没进入是因为没看上","text":"$Zoom(ZM)$zoom这种纯工具类app就是脆弱啊，被小扎一脚踹翻了…巨头之前没进入是因为没看上","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/925395360","isVote":1,"tweetType":1,"viewCount":1010,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":925399053,"gmtCreate":1587752286272,"gmtModify":1704365559391,"author":{"id":"3461415218066278","authorId":"3461415218066278","name":"cattyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461415218066278","authorIdStr":"3461415218066278"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>什么情况？","listText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>什么情况？","text":"$Zoom(ZM)$什么情况？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/925399053","isVote":1,"tweetType":1,"viewCount":1647,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":958078377,"gmtCreate":1591108215999,"gmtModify":1704194418800,"author":{"id":"3461415218066278","authorId":"3461415218066278","name":"cattyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461415218066278","authorIdStr":"3461415218066278"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>开始放量了","listText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>开始放量了","text":"$Zoom(ZM)$开始放量了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/958078377","isVote":1,"tweetType":1,"viewCount":1066,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":925208951,"gmtCreate":1588007175973,"gmtModify":1704366100796,"author":{"id":"3461415218066278","authorId":"3461415218066278","name":"cattyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461415218066278","authorIdStr":"3461415218066278"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>这票真坚挺","listText":"<a href=\"https://laohu8.com/S/ZM\">$Zoom(ZM)$</a>这票真坚挺","text":"$Zoom(ZM)$这票真坚挺","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/925208951","isVote":1,"tweetType":1,"viewCount":940,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":928543335,"gmtCreate":1586853258127,"gmtModify":1704362216743,"author":{"id":"3461415218066278","authorId":"3461415218066278","name":"cattyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3461415218066278","authorIdStr":"3461415218066278"},"themes":[],"htmlText":"现价138.9，这是来黑康希诺的？","listText":"现价138.9，这是来黑康希诺的？","text":"现价138.9，这是来黑康希诺的？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/928543335","repostId":"2027225484","repostType":2,"repost":{"id":"2027225484","pubTimestamp":1586845740,"share":"https://www.laohu8.com/m/news/2027225484?lang=&edition=full","pubTime":"2020-04-14 14:29","market":"us","language":"zh","title":"大摩料康希诺生物(06185.HK)预防新冠疫苗最快年底有机会获批 目标价102元","url":"https://stock-news.laohu8.com/highlight/detail?id=2027225484","media":"AAFN","summary":"摩根士丹利发表报告表示，康希诺生物 旗下预防新冠肺炎疫苗之Ad5-nCoV即将进入第二试验阶段，为全球首个进入第二试验阶段的疫苗，将会有500人以中、低剂量或安慰剂接种疫苗，并在第0、14、28和1","content":"<html><body><p><a href=\"https://laohu8.com/S/MS\">摩根士丹利</a>发表报告表示，康希诺生物 旗下预防新冠肺炎疫苗之Ad5-nCoV即将进入第二试验阶段，为全球首个进入第二试验阶段的疫苗，将会有500人以中、低剂量或安慰剂接种疫苗，并在第0、14、28和180天测试血清样品。该行估计，该疫苗最快於今年底或可获批，管理层更不排除除了中国，同时在海外国家进行後期试验。报告又指，希诺生物亦正考虑生产的各种选择，包括斥资3亿至5亿元人民币建立新生产线或寻找商业制造合作夥伴等，然而合同制造组织是不被允许在中国生产疫苗。如果成功获得批准，希诺生物计划至少向所有前线和高危人士提供疫苗。但是，最终剂量尚未确定，因此在此阶段很难评估产量。该行维持其「跑赢大市」评级，目标价为102元。(sw/da)~阿思达克财经新闻网址: www.aastocks.com</p></body></html>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>大摩料康希诺生物(06185.HK)预防新冠疫苗最快年底有机会获批 目标价102元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n大摩料康希诺生物(06185.HK)预防新冠疫苗最快年底有机会获批 目标价102元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-04-14 14:29 北京时间 <a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1008314&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>摩根士丹利发表报告表示，康希诺生物 旗下预防新冠肺炎疫苗之Ad5-nCoV即将进入第二试验阶段，为全球首个进入第二试验阶段的疫苗，将会有500人以中、低剂量或安慰剂接种疫苗，并在第0、14、28和180天测试血清样品。该行估计，该疫苗最快於今年底或可获批，管理层更不排除除了中国，同时在海外国家进行後期试验。报告又指，希诺生物亦正考虑生产的各种选择，包括斥资3亿至5亿元人民币建立新生产线或寻找商业...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1008314&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/24fa8350588843d92f819ac12ab5ce16","relate_stocks":{"MS":"摩根士丹利","06185":"康希诺生物"},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1008314&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2027225484","content_text":"摩根士丹利发表报告表示，康希诺生物 旗下预防新冠肺炎疫苗之Ad5-nCoV即将进入第二试验阶段，为全球首个进入第二试验阶段的疫苗，将会有500人以中、低剂量或安慰剂接种疫苗，并在第0、14、28和180天测试血清样品。该行估计，该疫苗最快於今年底或可获批，管理层更不排除除了中国，同时在海外国家进行後期试验。报告又指，希诺生物亦正考虑生产的各种选择，包括斥资3亿至5亿元人民币建立新生产线或寻找商业制造合作夥伴等，然而合同制造组织是不被允许在中国生产疫苗。如果成功获得批准，希诺生物计划至少向所有前线和高危人士提供疫苗。但是，最终剂量尚未确定，因此在此阶段很难评估产量。该行维持其「跑赢大市」评级，目标价为102元。(sw/da)~阿思达克财经新闻网址: www.aastocks.com","news_type":1},"isVote":1,"tweetType":1,"viewCount":1186,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
